Bivatop® 200 LA

Download the Bivatop® 200 LA Detailer

Product Information Sheet

Product Description

Bivatop® 200 LA is approved for use in beef and dairy cattle and is indicated in the treatment of:

  • Mastitis
  • Blackleg
  • Leptospirosis
  • Anaplasmosis (gallsickness)
  • Heartwater
  • Bacterial enteritis (scours)
  • Pneumonia
  • Actinobacillosis (wooden tongue)
  • Necrobacillosis
  • Navel/joint-ill and wound infections

Aids in the control and prevention of:

  • Bacterial respiratory infections associated with transport or shipping
  • Post-operative and post-parturient infections

Features & Benefits

Bivatop® 200 LA broad spectrum antibiotic – achieves rapid results with less tissue damage.1,2,3
But that’s not the only reason to reach for it.Bivatop® 200 LA’s SELECTCARRIER™ also achieves

  • High concentrations1
  • Long duration4,5
  • Fast recovery6

Dosage Information

1 ml per 10 kg body mass by deep intramuscular, subcutaneous or intravenous injection.

A single intramuscular or subcutaneous injection of 1 ml Bivatop® 200 LA/ 10 kg body mass equivalent to 20 mg oxytetracycline/ kg body mass is indicated to provide sustained antibiotic action over 3 to 5 days for the prevention or treatment of the susceptible disease condition of cattle where re-treatment is impractical due to various animal husbandry reasons. However in more chronic disease conditions a second treatment 48 to 72 hours following the first treatment may be administered.

Intravenous injection of BIivatop® 200 LA does not achieve any long-acting effect. If administered intravenously, BIivatop® 200 LA must be given slowly over a time period of at least 5 minutes to prevent potential collapse of the animal.

Do not administer more than 10 ml at any one subcutaneous or intramuscular injection site and not more than 1 to 2 ml per injection site in small calves.

Withdrawal period: The meat of treated animals may not be used for human consumption within 28 days, and the milk within 4 days, after the last treatment.

References:

1.In a study done. Data on file. Ingelheim Pharmaceuticals (Pty) Ltd, South Africa. Animal Health Division.

2.Data on file. Ingelheim Pharmaceuticals (Pty) Ltd, South Africa. Animal Health Division.

3.Data on file. Ingelheim Pharmaceuticals (Pty) Ltd, South Africa. Animal Health Division.

4.In a study on comparative administrative routes. Data on file. Ingelheim Pharmaceuticals (Pty) Ltd, South Africa. Animal Health Division.

5.Nouws JFM and Vree TB. Effect of injection site on the bioavailability of an oxytetracycline formulation in ruminant calves. Vet Quart 1983; 5(4):165-170.

6.In a study done. Data on file. Ingelheim Pharmaceuticals (Pty) Ltd, South Africa. Animal Health Division.